<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768582</url>
  </required_header>
  <id_info>
    <org_study_id>FYHIRB109001</org_study_id>
    <nct_id>NCT04768582</nct_id>
  </id_info>
  <brief_title>Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in Taiwanese ACS Patients</brief_title>
  <acronym>PREP-TAMI</acronym>
  <official_title>Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in Taiwanese Patients With Acute Myocardial Infarction: PREP-TAMI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Feng Yuan Hospital, Ministry of Health and Welfare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cheng-Hsin General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Feng Yuan Hospital, Ministry of Health and Welfare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prasugrel has a faster onset of action and greater platelet inhibition with less&#xD;
      inter-individual response variability than clopidogrel. Japan and Taiwan are the only two&#xD;
      nations where adjusted/Asian dose of prasugrel (loading dose (LD)/maintenance (MD): 20/3.75&#xD;
      mg) was approved for clinical use. However, there is no data regarding the effectiveness of&#xD;
      adjusted dose of prasugrel on platelet reactivity in Taiwanese patients with acute coronary&#xD;
      syndrome (ACS). This study aim to evaluate the pharmacodynamic of the Asian dose prasugrel on&#xD;
      the platelet reactivity after percutaneous coronary intervention (PCI) for patients with ACS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale and Background Prasugrel provides more potent and rapid platelet inhibition&#xD;
      compared to Clopidogrel.&#xD;
&#xD;
      Rapid and effective inhibition of the platelet P2Y12 receptor is of pivotal importance in&#xD;
      patients with AMI who undergo PCI.&#xD;
&#xD;
      Prasugrel (60 mg loading and 10 mg/day maintenance dose) is a new generation P2Y12 inhibitor&#xD;
      that achieves greater and faster platelet inhibition comparing with clopidogrel in patients&#xD;
      undergoing PCI.&#xD;
&#xD;
      As revealed by 2 head-to-head studies, reducing Prasugrel dosages to 20/3.75 LD/MD (mg) was&#xD;
      still efficacious but led to less bleeding events than the original 60/10 LD/MD (mg).&#xD;
&#xD;
      In TRITON-TIMI 38 trial, prasugrel was associated with not only significantly less ischemic&#xD;
      events but also more non-CABG TIMI major bleeding, as compared to Clopidogrel.&#xD;
&#xD;
      In the PRASFIT-ACS study from Japan (20 mg loading and 3.75 mg/day maintenance dose),&#xD;
      prasugrel was associated with a 23% reduction of MACE and the incidence of non-CABG major&#xD;
      bleeding was similar to clopidogrel.&#xD;
&#xD;
      There is NO data regarding the effectiveness of Japanese loading dose of prasugrel on&#xD;
      platelet reactivity in Taiwanese patients with AMI.&#xD;
&#xD;
      This study use PRU for efficacy and ISTH major bleeding for safety evaluations; the&#xD;
      anticipated results are prompt and effective platelet inhibition as well as comparably low&#xD;
      bleeding rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet reactivity (PRU) after loading of prasugrel at 12 hours</measure>
    <time_frame>12 hours</time_frame>
    <description>PRU 12 hours after a loading dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>platelet reactivity (PRU) after loading of prasugrel at 1 hour</measure>
    <time_frame>one hour</time_frame>
    <description>PRU 1 hour after a loading dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet reactivity (PRU) after loading of prasugrel at 3 hours</measure>
    <time_frame>3 hours</time_frame>
    <description>PRU 3 hours after a loading dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet reactivity (PRU) after loading of prasugrel at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>PRU 48 hours after a loading dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISTH Major bleeding</measure>
    <time_frame>day 7 after a loading dose of prasugrel</time_frame>
    <description>the definition recommended by the International Society on Thrombosis and Haemostasis (ISTH) defines major bleeding as fatal bleeding; symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular resulting in vision changes, retroperitoneal, intraarticular, pericardial</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Hemorrhage</condition>
  <condition>Treatment Side Effects</condition>
  <arm_group>
    <arm_group_label>Efient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACS patients who received oral Prasugrel after coronary angiography been done</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay</intervention_name>
    <description>The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).</description>
    <arm_group_label>Efient group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;=20&#xD;
&#xD;
          -  Mentally competent to provide an informed consent.&#xD;
&#xD;
          -  A person being diagnosed with acute coronary syndrome and arranged for a percutaneous&#xD;
             coronary intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of hemorrhagic stroke at any time in the past.&#xD;
&#xD;
          -  Active internal bleeding or has a history of a bleeding disorder (i.e. hemophilia).&#xD;
&#xD;
          -  Severe liver disease; for example, cirrhosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHEN RONG TSAO, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Feng Yuang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ms. Hao-Yien Pan</last_name>
    <phone>+88625271180</phone>
    <phone_ext>2400</phone_ext>
    <email>shine75726@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Feng Yuan Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>42055</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ChenRong Tsao, M.D.</last_name>
      <phone>+886425271180</phone>
      <phone_ext>5280</phone_ext>
      <email>tsaodr@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Feng Yuan Hospital, Ministry of Health and Welfare</investigator_affiliation>
    <investigator_full_name>Chen-Rong, Tsao M.D.</investigator_full_name>
    <investigator_title>Chief of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>VerifyNow-P2Y12 assay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

